ArticleJournal of medical biochemistry2025
Prognostic and clinical value of serum albumin, cortisol and TNF-a in treatment selection for advanced ovarian cancer patients.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the prognostic significance of pre-treatment serum albumin levels and assess their association with clinical outcomes and surgical decisions in advanced ovarian cancer (O C) patients. Cortisol and tumour necrosis factor-alpha (TN F-a) were also measured to explore potential but secondary relationships. Methods: A retrospective analysis was conducted on OC patients undergoing surgery at our hospital from June 2022 to June 2024 with complete clinical and pathological data. Patients were categorised into low ALB (< 35 g/L) and normal ALB (>35 g/L) groups based on pre-treatment serum ALB levels. Each group was further divided into primary debulking surgery (PDS) and neoadjuvant chemotherapy, followed by interval debulking surgery (NACT-IDS) subgroups. Clinicopathologic characteristics were analysed. Results: Pre-treatment serum ALB levels positively correlated with progression-free survival (PFS) (r= 0 .2 9 8 9 , P< 0.05) and overall survival (OS) (r= 0.2702, P< 0.05), with the low ALB group exhibiting significantly lower PFS and OS (P< 0.05). In the low ALB group, significant differences were observed between PDS and NACT-IDS in ascitic fluid level, R0 cytoreduction rate, postoperative complications, and length of stay (P< 0.05), though PFS and OS were comparable (P> 0.05). Similarly, in the normal ALB group, significant differences were noted in FIGO staging, ascitic fluid level, haemoglobin (HGB) levels, intra-operative haemorrhage, blood transfusion volume, R0 cytoreduction rate, and length of stay (P< 0.05), while PFS and OS remained unaffected by treatment type (P> 0.05). Additionally, C-reactive protein (CRP) levels were significantly higher in the low ALB group (6.5± 1.1 mg/L vs 5.2± 1.0 mg/L, P< 0.05), indicating greater inflammation, whereas HGB levels were substantially lower (110.4± 15.8 g/L vs 118.7± 10.5 g/L, P= 0.021), reflecting poorer nutritional status. TNF-a levels showed a non-significant upward trend (P= 0.058), while cortisol levels were similar between groups (P= 0.073). Conclusions: Selecting NACT-IDS for advanced OC patients with hypoalbuminemia may help reduce the incidence of postoperative complications and improve the likelihood of achieving optimal cytoreduction. While survival outcomes (PFS and OS) did not significantly differ between treatment approaches in this study, the observed surgical benefits suggest that hypoalbuminemia could be considered a supportive factor in treatment planning. However, this indicator should be used cautiously and in conjunction with other clinical parameters until further evidence is available. The roles of TNF-a and cortisol in this context remained inconclusive and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.